Trial Profile

A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms IMMUTACE

Most Recent Events

07 Jun 2022 Updated efficacy results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
10 Mar 2022 Status changed from active, no longer recruiting to completed.
13 Jul 2020 Planned End Date changed from 1 Sep 2022 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com